RxDoctor Payments Data

Carlos Berrios Rosado, MD

Neurology · Ponce, PRNPI 1508026568

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.6% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 49.4% of the total.

$2,362in general payments, 2019–2025

Across 111 payments — averaging $21.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$1K
  • Biohaven Pharmaceutical Holding Company Ltd.$276
  • Kyowa Kirin, Inc.$205
  • Biohaven Pharmaceuticals, Inc.$185
  • Amgen$136
  • AbbVie$106
  • plus $288 from 12 others

What the payments were for

  • Food & beverage$2,16392%
  • Education$1998%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,362 in reported general payments places this provider in the 60th percentile of 129 neurology providers in Puerto Rico.

See all neurology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$203,915
Medicare patients
456
Services billed
8,610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine23$115,900
Teriflunomide14$80,725
Aimovig AutoinjectorErenumab-Aooe43$53,384
FingolimodFingolimod Hcl19$48,834
Nurtec OdtRimegepant Sulfate34$45,334
RytaryCarbidopa/Levodopa46$38,582
EliquisApixaban33$35,461
Emgality PenGalcanezumab-Gnlm23$32,511
NeuproRotigotine30$29,331
XareltoRivaroxaban26$24,807
NourianzIstradefylline11$23,235
ZonegranZonisamide11$20,525
LamictalLamotrigine11$14,280
Memantine Hcl ErMemantine Hcl69$10,033
Topiramate ErTopiramate19$10,013

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$1,167$115,90023 claims
PfizerNurtec Odt, Eliquis$24$80,79667 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$29$41,36684 claims
Kyowa Kirin, Inc.Nourianz$205$23,23511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 129 neurology providers in Puerto Rico.

Other neurology in Ponce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →